NCT03901196

Brief Summary

Evaluate the feasibility of performing a multi-elemental imaging analysis of lung specimens from patients with ILDs, with an technology named LIBS (Laser Induced-Breakdown Spectroscopy)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
86

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2020

Longer than P75 for all trials

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 28, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 3, 2019

Completed
10 months until next milestone

Study Start

First participant enrolled

January 22, 2020

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 9, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 9, 2024

Completed
Last Updated

August 30, 2024

Status Verified

August 1, 2024

Enrollment Period

4.2 years

First QC Date

March 28, 2019

Last Update Submit

August 29, 2024

Conditions

Keywords

Laser Induced Breakdown SpectroscopyMulti elemental imaging

Outcome Measures

Primary Outcomes (1)

  • Generation of multi-elemental images in tissues with LIBS

    Evaluation of the feasibility of collecting and describing LIBS multi-elemental images of lung specimens originating from patients with ILDs

    Within a month after reception of the biopsy by the analytical laboratory

Secondary Outcomes (3)

  • Description of elemental distribution in the specimens

    Within a month after reception of the biopsy by the analytical laboratory

  • Interpretation of the elemental maps

    Within a month after reception of the biopsy by the analytical laboratory

  • Comparison of the elemental distributions with results of other mineralogical investigations

    Within a month after reception of the biopsy by the analytical laboratory

Study Arms (1)

Interstitial Lung Disease

Ex : sarcoidosis, IPF

Diagnostic Test: Elemental analysis

Interventions

Elemental analysisDIAGNOSTIC_TEST

LIBS multi elemental analysis of the specimen

Interstitial Lung Disease

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults with Interstitial Lung Disease

You may qualify if:

  • Patient with ILD
  • Patient informed, and agreed to participate

You may not qualify if:

  • Patient opposed to participating in the study.
  • Patient without available specimen.
  • Patient under legal protection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Grenoble Alpes University Hospital

Grenoble, 38043, France

Location

CHRU de LILLE

Lille, 59000, France

Location

CHU de Lyon HCL - GH Sud

Lyon, 69310, France

Location

Hôpital Louis Pradel

Lyon, 69677, France

Location

Related Publications (2)

  • Busser B, Moncayo S, Trichard F, Bonneterre V, Pinel N, Pelascini F, Dugourd P, Coll JL, D'Incan M, Charles J, Motto-Ros V, Sancey L. Characterization of foreign materials in paraffin-embedded pathological specimens using in situ multi-elemental imaging with laser spectroscopy. Mod Pathol. 2018 Mar;31(3):378-384. doi: 10.1038/modpathol.2017.152. Epub 2017 Nov 17.

  • Busser et al., Coord Chem Rev, 2018, 358, p70

    RESULT

MeSH Terms

Conditions

Lung Diseases, InterstitialSarcoidosisIdiopathic Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesHypersensitivity, DelayedHypersensitivityImmune System DiseasesPulmonary Fibrosis

Study Officials

  • Benoit Busser, PharmD, PhD

    Grenoble Alpes University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 28, 2019

First Posted

April 3, 2019

Study Start

January 22, 2020

Primary Completion

April 9, 2024

Study Completion

April 9, 2024

Last Updated

August 30, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations